Perceptive Advisors LLC Travere Therapeutics, Inc. Transaction History

Perceptive Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $2.36 Million - $5.33 Million	309,252 Added 340.78%	400,000 $3.58 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $11 Million - $13.7 Million	-479,336 Reduced 84.08%	90,748 $2.24 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $26.7 Million - $38.3 Million	-1,275,471 Reduced 69.11%	570,084 $13.8 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $2.92 Million - $3.74 Million	-120,000 Reduced 6.11%	1,845,555 $57.3 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $1.56 Million - $3 Million	120,000 Added 6.5%	1,965,555 $47.7 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $20.5 Million - $38.4 Million	-1,452,864 Reduced 44.05%	1,845,555 $26.9 Million
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $4.56 Million - $6.2 Million	-195,188 Reduced 5.59%	3,298,419 $82.4 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $67 Million - $97.4 Million	3,493,607 New	3,493,607 $95.2 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.